Wall street was lagging despite better-than-expected US jobs data as traders feared flaring tensions between the US and China
Britain’s blue-chip benchmark finished the day up around five points or 0.09% at 6,032. Over the week as a whole, the index added around 2.2%.
European stocks are fractionally higher this afternoon as the US non-farm payrolls report was well-received, noted analyst David Madden, at CMC Markets, adding that the report showed that the jobs market was recovering.
Wall Street was lagging despite the jobs report as traders were fearful about the heightened tensions with China.
Gold lost around 1.48% to US$2,038 an ounce, while the pound was down 0.72% against the US dollar.
In US and Canada, Wall Street shares were seeing red in early deals. The Dow Jones Industrial Average shed over 43 at 27,343. The S&P 500 lost 0,14 at 3,349. The tech heavy Nasdaq was off around four points at 11,103. In Canada and Toronto, the S&P/TSX index shed around 26 at 16,553.
Orgenesis touts 2Q revenue jump from its POCare network, advances coronavirus vaccine platform.
First Mining Gold and Treasury Metals close deal to merge the Goldlund and Goliath gold projects in Ontario.
Blackrock Gold bolsters board with sales and corporate finance professional.
GoviEx Uranium closes first tranche of fully subscribed non-brokered private placement offering for gross proceeds of approximately $5M.
Binovi Technologies names former White House Fellow Eric Phillips as strategic advisor.
Co-Diagnostics says coronavirus detection test authorized for use in Australia.
Gold Resource Corp welcomes Kimberly Perry as its new finance chief as John Labate retires.
CytoDyn seeks UK approval for its flagship drug leronlimab for HIV and coronavirus.
Silvercorp Metals reports increased revenue and net income in first quarter, lower production costs.
Nomad Royalty Company posts strong revenue from a growing portfolio of global assets in its inaugural quarter.
The articles are for information purposes only and Precise Investors shall not be held responsible for any errors, omissions or inaccuracies within it. Any rules or regulations mentioned within the website are those relevant at the time of publication and may not be the most up-to-date.
Precise Investors does not endorse any of the products or services that appear on it or are linked to it and are not liable for any action that you may take as a result of the content of this website, or losses or damage you may incur doing so.
There is no obligation to purchase anything but, if you decide to do so, you are strongly advised to consult a professional adviser before making any investment decisions.
Please remember that investments of any type may rise or fall and past performance does not guarantee future performance in respect of income or capital growth; you may not get back the amount you invested.